blinatumomab,CD3/CD19T,:

Marion Subklewe1, Giulia Magno2, Christina Gebhardt3

  • 1Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany; German Cancer Consortium (DKTK), Munich and Berlin sites, and German Cancer Research Center, Heidelberg, Germany.

European journal of cancer (Oxford, England : 1990)
|May 1, 2024
PubMed
概括

双特异性T细胞参与者Blinatumomab通过耗尽B细胞显示出治疗严重系统性硬化症的前景. 这为自身免疫性疾病的CD19CART细胞提供了更安全的替代方案.